Twitter Facebook YouTube Google+ LinkedIn RSS Feed

LDL Particle Concentration NMR, Plasma [A Test in Focus]

ldlp-brochureTo offer a more complete picture of cardiovascular disease (CVD) risk, Mayo Medical Laboratories is now performing nuclear magnetic resonance (NMR) lipoprotein testing using Liposcience’s Vantera® Clinical Analyzer.

The Vantera Clinical Analyzer can identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. This analysis provides physicians and patients with a detailed assessment of CVD risk from a single blood test that measures the concentration of LDL-P and other lipoprotein information. LDL-P may assist in determining treatment strategies and clinical decision making for personalized LDL management.

  • LDL Particle Concentration NMR, Plasma, TLDLP
    Download pdf-icon | View in Test Online Catalog link



  • Assessment and management of a patient’s risk for cardiovascular disease and events
  • Test ID: TLDLP — Plasma EDTA, 1 mL, refrigerated
  • Low-density lipoprotein cholesterol (LDL-C) remains the primary focus for cardiovascular risk assessment and evaluation of pharmacologic effectiveness based on treatment target goals.
  • Measurement of LDL-C may not accurately reflect the true burden of atherogenic LDL particles.
  • The total LDL particle concentration (LDL-P) is a measure of the total number of atherogenic particles, whereas LDL-C is only an estimate of the cholesterol contained within LDL particles.
  • LDL-P may aid in determining treatment strategies and clinical decision making for personalized LDL management.
  • Nuclear Magnetic Resonance (NMR)


  • Day(s) and Time(s) Test Performed: Monday through Friday; Continuous
  • Analytic Time: Same day/5 days

Additional Information/Resources

Who should be tested?

LDL-P by NMR is appropriate for patients being managed with a lipid-lowering therapy, intensive lifestyle management, or who meet at least 1 of the following criteria1:

  • Known cardiovascular disease
  • Coronary heart disease risk equivalents, such as type 2 diabetes mellitus or chronic kidney disease
  • Multiple cardiometabolic risk factors that define metabolic syndrome:
    • High blood pressure or on antihypertensive medication
    • High blood sugar
    • High triglycerides
    • Low high-density lipoprotein cholesterol (HDL-C)
    • Abdominal obesity

What’s the relationship of LDL-P to cardiovascular disease?

Historically, clinicians have determined a patient’s risk for cardiovascular disease by measuring lipids such as LDL-C, HDL-C, and triglycerides. More recently, it’s been shown that measurement of lipoprotein particles, the containers that carry cholesterol, may be beneficial for patient management.

Among patients at risk for cardiovascular disease, about one-half have high LDL-P despite optimal levels of LDL-C2,3. For these patients, measuring and lowering LDL-P should be considered a primary goal of therapy due to its stronger association with cardiovascular risk.


  1. Rosenson RS, Davidson, MH, Pourfarzib R: Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010:213(1):1-7
  2. Sachdeva A, Cannon CP, Deedwania PC, et al: Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 2009;157(1):111-117
  3. deGoma EM, Knowles JW, Angeli F, et al: The evolution and refinement of traditional risk factors for cardiovascular disease. Cardiol Rev 2012 May-Jun;20(3):118-129

About Andy Tofilon

Andy is a Marketing Segment Manager for Mayo Medical Laboratories.
This entry was posted in A Test in Focus, Cardiology, Lipid / Metabolic, Testing.